Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 14, 2024; 30(18): 2479-2481
Published online May 14, 2024. doi: 10.3748/wjg.v30.i18.2479
Options and survival benefits of conversion therapy for unresectable hepatocellular carcinoma
Wong Hoi She, Tan To Cheung
Wong Hoi She, Tan To Cheung, Department of Surgery, The University of Hong Kong, Hong Kong 999077, China
Author contributions: She WH performed the research and wrote the manuscript; Cheung TT provided supervision. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors do not have any conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tan To Cheung, MD, Professor, Department of Surgery, The University of Hong Kong, No. 102 Pok Fu Lam Road, Hong Kong 999077, China. tantocheung@hotmail.com
Received: October 19, 2023
Revised: February 13, 2024
Accepted: April 22, 2024
Published online: May 14, 2024
Processing time: 205 Days and 9.9 Hours
Core Tip

Core Tip: In addition to transarterial chemoembolization (TACE), immunotherapy should also be among the options for conversion therapy for rendering unresectable hepatocellular carcinoma suitable for resection. For patients unsuitable for TACE, immunotherapy can be an alternative.